A Study of the Intestinal Microbiome in Patients with Cirrhosis

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06808698

Acronym

IIT_MicroB

Enrollment

100

Registered

2025-02-05

Start date

2025-06-01

Completion date

2025-12-01

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Keywords

liver cirrhosis

Brief summary

This study aims to establish a cohort for analyzing the gut microbiome of patients with liver cirrhosis and to identify factors that influence the prognosis of these patients.

Interventions

OTHERDetermine the gut microbiome at baseline and 12 months.

There is no separate treatment, surgery, or other intervention.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Aged 19 years or older: 2. Patients visiting the hospital with liver cirrhosis. 3. Patients diagnosed with liver cirrhosis who can understand the information provided to them or their representatives and have voluntarily given written consent to participate in this study

Exclusion criteria

1. Cases not meeting the inclusion criteria 2. Patients who refuse participation 3. Patients who have taken or been administered antibiotics within the past 2 weeks or are scheduled to take or receive antibiotics during the study period 4. Cases where the diagnosis is unclear 5. Cases with incomplete data or missing investigation items 6. Individuals deemed unsuitable by the principal investigator for other reasons

Design outcomes

Primary

Measure	Time frame	Description
Incidence rate of non-targeted complications according to changes in the gut microbiome	baseline, Month 12	We observed changes in the gut microbiome of the subjects participating in the study at baseline and 12 months, and confirmed the incidence of non-target complications accordingly.

Secondary

Measure	Time frame	Description
Liver cancer incidence rate according to gut microbiome composition	Baseline, 12 Month	We observed changes in the gut microbiome of the subjects participating in the study at baseline and 12 months, and confirmed the liver cancer incidence rate accordingly.

Contacts

Primary ContactHye Won Professor Lee

lorry-lee@yuhs.ac+822-2228-0813

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026